Branford, Connecticut Clinical Trials

A listing of Branford, Connecticut clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

alzheimer's disease
positron emission tomography
mini-mental state examination
flortaucipir
florbetapir
Institute for Neurodegenerative Disorders
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +85 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

treatment regimen
lasmiditan
migraine
ly573144
preventive medication
Yale New Haven Children's Hospital
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

serum pregnancy test
ascites
non-target
platinum-based chemotherapy
plain x-ray
Smilow Cancer Hospital at Yale New Haven
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

hras gene
recurrent thyroid gland carcinoma
donor lymphocyte infusion
HRAS
nitrosoureas
Yale University
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

metastatic malignant solid tumor
kras
kras g12c mutation
solid tumor
solid tumour
Yale Cancer Center
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combination therapy
testosterone
antiandrogens
antiandrogen therapy
taxane
Yale School of Medicine
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of [18F]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.

radiopharmaceuticals
Invicro, a Konica Minolta company
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
imiglucerase
gaucher disease
deficiency
Investigational Site Number 840047
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840047
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

myozyme
replacement therapy
glycogen storage disease type ii
gaa gene
deficiency
Investigational Site Number 840047
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations